WO2005072306A3 - Reelin deficiency or dysfunction and methods related thereto - Google Patents

Reelin deficiency or dysfunction and methods related thereto Download PDF

Info

Publication number
WO2005072306A3
WO2005072306A3 PCT/US2005/002177 US2005002177W WO2005072306A3 WO 2005072306 A3 WO2005072306 A3 WO 2005072306A3 US 2005002177 W US2005002177 W US 2005002177W WO 2005072306 A3 WO2005072306 A3 WO 2005072306A3
Authority
WO
WIPO (PCT)
Prior art keywords
patient
reelin
dysfunction
deficiency
dha
Prior art date
Application number
PCT/US2005/002177
Other languages
French (fr)
Other versions
WO2005072306A2 (en
Inventor
John P Morseman
Mark W Moss
Lorie A Ellis
Original Assignee
Martek Biosciences Corp
John P Morseman
Mark W Moss
Lorie A Ellis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US53760004P priority Critical
Priority to US60/537,600 priority
Priority to US60521904P priority
Priority to US60/605,219 priority
Application filed by Martek Biosciences Corp, John P Morseman, Mark W Moss, Lorie A Ellis filed Critical Martek Biosciences Corp
Publication of WO2005072306A2 publication Critical patent/WO2005072306A2/en
Publication of WO2005072306A3 publication Critical patent/WO2005072306A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system

Abstract

A method of measuring Reelin as a biomarker, to non-destructively assess or predict DHA levels in the brain and in other, currently inaccessible or difficult-to-access, key components of the central nervous system (CNS) is described. Also described is a method to prevent, delay the onset of, or treat Reelin deficiency or dysfunction and/or a disease or condition associated with Reelin deficiency or dysfunction, comprising administering to a patient diagnosed with or suspected of having a Reelin deficiency or dysfunction an amount of a PUFA, and particularly an omega-3 PUFA, and more particularly, docosahexaenoic acid (DHA) or a precursor or source thereof, to compensate for the effects of Reelin deficiency or dysfunction in the patient. Also described is a method to prevent or reduce development defects or disorders associated with Reelin dysfunction or deficiency through the supplemental use of polyunsaturated fatty acids (PUFAs- unsaturated fatty acids having two or more double bonds), and particularly highly unsaturated fatty acids (HUFAs- unsaturated fatty acids having three or more double bonds), and more particularly a HUFA selected from arachidonic acid (ARA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA), and even more particularly omega-3 HUFAs, and more particularly DHA, to: compensate for reduced fatty acid binding protein or function thereof in the patient; compensate for reduced brain lipid binding protein or function thereof in the patient; improve the activity of fatty acid binding proteins in the patient; increase the expression of brain lipid binding proteins (BLBPs) in the patient; improve at least one parameter of the mechanism of action of brain lipid binding proteins in the patient; overcome a deficiency of DHA in central nervous system (CNS) structures and improve the resulting function thereof; increase the incorporation of functional DHA and other PUFAs into the phospholipid membranes of glial cells and neurons in the patient; increase the level of Reelin and/or improve the activity of Reelin in the patient; and/or improve at least one symptom of a disease or condition associated with Reelin deficiency or dysfunction.
PCT/US2005/002177 2004-01-19 2005-01-19 Reelin deficiency or dysfunction and methods related thereto WO2005072306A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US53760004P true 2004-01-19 2004-01-19
US60/537,600 2004-01-19
US60521904P true 2004-08-27 2004-08-27
US60/605,219 2004-08-27

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/597,304 US20090215896A1 (en) 2004-01-19 2005-01-19 Reelin deficiency or dysfunction and methods related thereto
EP05706056A EP1713463A4 (en) 2004-01-19 2005-01-19 Reelin deficiency or dysfunction and methods related thereto
JP2006551363A JP2007524674A (en) 2004-01-19 2005-01-19 Reelin deficiency or dysfunction and related methods
CA002551882A CA2551882A1 (en) 2004-01-19 2005-01-19 Reelin deficiency or dysfunction and methods related thereto
AU2005208832A AU2005208832A1 (en) 2004-01-19 2005-01-19 Reelin deficiency or dysfunction and methods related thereto

Publications (2)

Publication Number Publication Date
WO2005072306A2 WO2005072306A2 (en) 2005-08-11
WO2005072306A3 true WO2005072306A3 (en) 2006-03-09

Family

ID=34830449

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/002177 WO2005072306A2 (en) 2004-01-19 2005-01-19 Reelin deficiency or dysfunction and methods related thereto

Country Status (6)

Country Link
US (1) US20090215896A1 (en)
EP (1) EP1713463A4 (en)
JP (1) JP2007524674A (en)
AU (1) AU2005208832A1 (en)
CA (1) CA2551882A1 (en)
WO (1) WO2005072306A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4993852B2 (en) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 Composition having a preventive or ameliorating effect on symptoms or diseases accompanied by behavioral abnormalities caused by stress
BRPI0515727A (en) * 2004-11-08 2008-08-05 Univ Duke biomarker for heart failure
JP5697293B2 (en) * 2005-06-30 2015-04-08 サントリーホールディングス株式会社 Composition having an improving effect on lowering of higher brain function due to organic brain injury
JP5967855B2 (en) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 Composition having an activity of reducing daytime activity and / or depressive symptoms
AU2006269405B2 (en) * 2005-07-08 2013-01-17 Dsm Ip Assets B.V. Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions
KR101578498B1 (en) 2006-12-28 2015-12-18 산토리 홀딩스 가부시키가이샤 Nerve regeneration agent
WO2010045490A2 (en) * 2008-10-15 2010-04-22 Ridge Diagnostics, Inc. Human biomarker hypermapping for depressive disorders
JP5934102B2 (en) 2009-10-30 2016-06-15 レトロトップ、 インコーポレイテッドRetrotope, Inc. Mitigation of oxidative stress disorder by PUFA derivatives
WO2011127587A1 (en) * 2010-04-14 2011-10-20 The Royal Institution For The Advancement Of Learning / Mcgill University Biomarkers for multiple sclerosis
CA2834341A1 (en) 2011-04-26 2012-11-01 Retrotope, Inc. Oxidative retinal diseases
KR102014526B1 (en) 2011-04-26 2019-08-26 레트로토프 인코포레이티드 Disorders implicating pufa oxidation
US10154983B2 (en) * 2011-04-26 2018-12-18 Retrotope, Inc. Neurodegenerative disorders and muscle diseases implicating PUFAs
US9668942B2 (en) 2012-02-17 2017-06-06 Alcresta Therapeutics, Inc. Methods, compositions, and devices for supplying dietary fatty acid needs
CN103820528B (en) * 2012-11-16 2015-02-18 北京大学 New applications of Reelin and antagonist thereof in staging and prognosis of myeloma patient
CN105307719B (en) 2013-05-30 2018-05-29 格雷厄姆·H.·克雷西 Local nerve stimulation instrument
US10258590B2 (en) 2015-10-14 2019-04-16 Alcresta Therapeutics, Inc. Enteral feeding device and related methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516800A (en) * 1992-11-26 1996-05-14 Scotia Holdings Plc Schizophrenia
US6197764B1 (en) * 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
CA2010511A1 (en) * 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
CA2052577C (en) * 1991-10-01 2000-01-11 Michael John Tisdale Therapeutic uses of eicosapentaenoic acid
GB9510636D0 (en) * 1995-05-25 1995-07-19 Scotia Holdings Plc Fatty acid treatment
IL122405A (en) * 1995-06-07 2003-04-10 Martek Biosciences Corp Methods for preparation of pharmaceutical composition for treatment of specific diseases using oils enriched in dha
GB9617847D0 (en) * 1996-08-27 1996-10-09 Scotia Holdings Plc Fatty acid treatment
BR9713479A (en) * 1996-10-11 2000-04-11 Scotia Holdings Plc Pharmaceutical preparation comprising eicosapentaenoic acid and / or stearidonic acid.
JPH10139675A (en) * 1996-11-05 1998-05-26 Otsuka Yakuhin Kogyo Kk Production of agent for allowing brain to be healthy and vital
WO1998048788A1 (en) * 1997-04-29 1998-11-05 Scotia Holdings Plc Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants
AU5928599A (en) * 1999-09-09 2001-04-10 Efa Sciences Llc. Methods for treating cell proliferative disorders including cancer
US6380253B1 (en) * 2000-01-05 2002-04-30 Efa Sciences Llc Method of stabilizing and potentiating the action of anti-angiogenic substances
WO2001049282A2 (en) * 2000-01-06 2001-07-12 Martek Biosciences Corporation Therapeutic preparations of highly unsaturated fatty acids
US7208180B2 (en) * 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
GB0016045D0 (en) * 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
US20020077317A1 (en) * 2000-12-15 2002-06-20 Das Undurti Narasimha Method of potentating the action of 2-methoxyoestradiol, statins and C-peptide of proinsulin
ES2238568T3 (en) * 2001-05-30 2005-09-01 Laxdale Limited Use of coenzyme q (ubiquinone) and eicosapentaenoic acid (epa) for the treatment of non-hodgkin lymphoma and psychiatric or neurological disorders.
JP2003048831A (en) * 2001-08-02 2003-02-21 Suntory Ltd Composition having preventing and ameliorating action on symptom or disease caused by decrease in brain function
US20030165485A1 (en) * 2001-11-09 2003-09-04 Goran Bertilsson Functional role and potential therapeutic use of Reelin, Gas6 and Protein S in relation to adult neural stem or progenitor cells
NL1019368C2 (en) * 2001-11-14 2003-05-20 Nutricia Nv Preparation for improving receptor performance.
WO2003063110A1 (en) * 2002-01-16 2003-07-31 Regents Of The University Of Minnesota Marker for psychiatric conditions
AU2003255863A1 (en) * 2002-07-31 2004-02-23 Helfried Hans Rudolf Crede Pharmaceutical composition containing black cumin oil, flax oil and borago oil
GB0228079D0 (en) * 2002-12-02 2003-01-08 Laxdale Ltd Huntington's Disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516800A (en) * 1992-11-26 1996-05-14 Scotia Holdings Plc Schizophrenia
US6197764B1 (en) * 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1713463A4 *

Also Published As

Publication number Publication date
WO2005072306A2 (en) 2005-08-11
AU2005208832A1 (en) 2005-08-11
JP2007524674A (en) 2007-08-30
US20090215896A1 (en) 2009-08-27
CA2551882A1 (en) 2005-08-11
EP1713463A2 (en) 2006-10-25
EP1713463A4 (en) 2009-03-18

Similar Documents

Publication Publication Date Title
Orr et al. Unesterified docosahexaenoic acid is protective in neuroinflammation
von Schacky Omega-3 fatty acids in cardiovascular disease–an uphill battle
Trépanier et al. N-3 polyunsaturated fatty acids in animal models with neuroinflammation: An update
Roberts et al. Beneficial and cautionary outcomes of resveratrol supplementation in pregnant nonhuman primates
Calder Very long-chain n-3 fatty acids and human health: fact, fiction and the future
Gertsik et al. Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder
Bos et al. Effects of omega-3 polyunsaturated fatty acids on human brain morphology and function: What is the evidence?
Frisardi et al. Glycerophospholipids and glycerophospholipid-derived lipid mediators: a complex meshwork in Alzheimer’s disease pathology
Thies et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial
Montine et al. Lipid peroxidation in aging brain and Alzheimer’s disease
Calder Polyunsaturated fatty acids, inflammation, and immunity
Sapieha et al. 5-Lipoxygenase metabolite 4-HDHA is a mediator of the antiangiogenic effect of ω-3 polyunsaturated fatty acids
Von Schacky Prophylaxis of atherosclerosis with marine omega-3 fatty acids: a comprehensive strategy
Bannenberg et al. Specialized pro-resolving lipid mediators in the inflammatory response: An update
CA1227429A (en) Pharmaceutical and dietary composition
Kunešová et al. The influence of n-3 polyunsaturated fatty acids and very low calorie diet during a short-term weight reducing regimen on weight loss and serum fatty acid composition in severely obese women.
Toomey et al. Profound resolution of early atherosclerosis with conjugated linoleic acid
McNamara et al. Selective deficits in erythrocyte docosahexaenoic acid composition in adult patients with bipolar disorder and major depressive disorder
Calder Polyunsaturated fatty acids and inflammatory processes: new twists in an old tale
Haydon et al. Astrocyte control of synaptic transmission and neurovascular coupling
Kendall et al. Bioactive lipid mediators in skin inflammation and immunity
Monroig et al. Expression of long-chain polyunsaturated fatty acid (LC-PUFA) biosynthesis genes during zebrafish Danio rerio early embryogenesis
Kalyvas et al. Differing roles for members of the phospholipase A2 superfamily in experimental autoimmune encephalomyelitis
Sohrabi et al. Evaluation of the effect of omega-3 fatty acids in the treatment of premenstrual syndrome:“a pilot trial”
Manku et al. Essential fatty acids in the plasma phospholipids of patients with atopic eczema

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

WWE Wipo information: entry into national phase

Ref document number: 2005208832

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2551882

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2005208832

Country of ref document: AU

ENP Entry into the national phase in:

Ref document number: 2005208832

Country of ref document: AU

Date of ref document: 20050119

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 10597304

Country of ref document: US

Ref document number: 2006551363

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005706056

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200580008876.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2005706056

Country of ref document: EP